Sponsor Check › Nex Cubed › Issuer
Corporation · organized in DELAWARE · formed Over five years ago · SAN DIEGO, CA · SEC CIK 1892786
Part of sponsor group: Nex Cubed (3 issuers, 9 filings) · grouped because: shared people · confidence 70% · Not the same sponsor? Request a correction
Data last updated: Oct 23, 2026, 5:45 PM ET · Latest filing by this issuer: Oct 21, 2026 · Courts (RECAP) last checked: not yet · SEC enforcement last checked: not yet
The five facts investors ask about first. Each section states what was searched and when. Items still in human review are not shown.
Not yet searched.
Sources to be searched: CourtListener / RECAP archive (federal district courts, federal bankruptcy courts). State courts: not yet searched. PACER: not searched (RECAP only). · Search queued. Results are added automatically; check back later or follow this page to be notified.
Not yet searched.
Sources to be searched: SEC litigation releases and administrative proceedings — respondent names in the sec.gov index titles (30,205 releases, 1995-09-19 to 2026-10-23); release text is read only to confirm a candidate. Names that appear only in the body of a release are not found. State securities regulator actions: not yet searched. · Search queued. Results are added automatically; check back later or follow this page to be notified.
Not yet searched.
Sources to be searched: Federal bankruptcy courts via CourtListener / RECAP archive (federal district courts, federal bankruptcy courts). State courts: not yet searched. PACER: not searched (RECAP only). · Search queued. Results are added automatically; check back later or follow this page to be notified.
Coming soon.
What will be compared: what the sponsor says publicly (website, marketing materials, claimed profile) against what public records show — SEC Form D filings, Form ADV adviser registration, and state business records. Every comparison is reviewed by a person before it is published.
No comparisons published yet.
Sources to be compared: sponsor public claims · SEC Form D · SEC Form ADV (IAPD) · state business records · As of Oct 23, 2026, 9:13 PM ET.
0 of 5 offerings report sales commissions; 0 report finder's fees; 0 report proceeds to related persons.
| Source | Offering (latest filing) | Sales commissions | Finder's fees | To insiders | Paid to sell it |
|---|---|---|---|---|---|
| EDGAR ↗ | Nov 9, 2021 D File 021-420411 | $0 | $0 | $0 | None listed |
| EDGAR ↗ | Feb 7, 2024 D File 021-504558 | $0 | $0 | $0 | None listed |
| EDGAR ↗ | Oct 15, 2024 D File 021-526663 | $0 | $0 | $0 | None listed |
| EDGAR ↗ | Nov 14, 2025 D File 021-564110 | $0 | $0 | $0 | None listed |
| EDGAR ↗ | Oct 21, 2026 D File 021-602012 | $0 | $0 | $0 | None listed |
As reported by the issuer on Form D (Items 12–15), latest filing per offering. "To insiders" = gross proceeds used for payments to executive officers, directors or promoters. "—" = not reported on that filing. Amounts marked (est.) were reported as estimates.
Each filing as reported by the issuer. Open a row for the full plain-English detail.
| Filing | Form D filed Oct 21, 2026 SEC file no. 021-602012 · accession 0001892786-26-000001 |
|---|---|
| Raise progress | $5,115,268 sold of $8,000,000 offered (64%) · $2,884,732 remaining |
| Filing timing | Date of first sale: Oct 15, 2026 · Form D filed: Oct 21, 2026 (6 days after first sale) Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn. |
| Time since first sale | 9 days (0.0 years) |
| Annual amendments | Issuer reported the offering is not expected to last more than one year. Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn. |
| Investors | 37 total · issuer reported no non-accredited investors |
| Exemption claimed | Rule 506(b) — no general advertising; up to 35 non-accredited investors allowed |
| Minimum investment accepted | $0 |
| Securities offered | Equity |
| Industry / issuer size | Other · revenue range: Decline to Disclose |
| Who is paid to sell it | No sales compensation recipients listed on this filing. |
| Money to insiders | Sales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0 |
| Signed by | Daniel Haders, President (Oct 21, 2026) |
| Market context | Minimum investment: $0. Typical range for similar offerings: $5,000–$50,000. Offering size: $8,000,000. Typical range: $500,000–$7,000,000. Investors: 37. Typical range: 2–14. "Similar" = Other offerings claiming 506(b) filed in the last 5 years (18,678 filings); ranges are the middle half (25th–75th percentile). No ranking or score. |
| Source | This filing on SEC EDGAR ↗ · retrieved from the EDGAR daily index |
| Filing | Form D filed Nov 14, 2025 SEC file no. 021-564110 · accession 0001892786-25-000008 |
|---|---|
| Raise progress | $3,260,000 sold of $5,000,000 offered (65%) · $1,740,000 remaining |
| Filing timing | Date of first sale: Oct 29, 2025 · Form D filed: Nov 14, 2025 (16 days after first sale) Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn. |
| Time since first sale | 360 days (1.0 years) |
| Annual amendments | Issuer reported the offering is not expected to last more than one year. Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn. |
| Investors | 10 total · issuer reported no non-accredited investors |
| Exemption claimed | Rule 506(b) — no general advertising; up to 35 non-accredited investors allowed |
| Minimum investment accepted | $0 |
| Securities offered | Equity |
| Industry / issuer size | Other · revenue range: Decline to Disclose |
| Who is paid to sell it | No sales compensation recipients listed on this filing. |
| Money to insiders | Sales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0 |
| Signed by | Daniel Haders, President (Nov 13, 2025) |
| Market context | Minimum investment: $0. Typical range for similar offerings: $5,000–$50,000. Offering size: $5,000,000. Typical range: $500,000–$7,000,000. Investors: 10. Typical range: 2–14. "Similar" = Other offerings claiming 506(b) filed in the last 5 years (18,678 filings); ranges are the middle half (25th–75th percentile). No ranking or score. |
| Source | This filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set |
| Filing | Form D filed Oct 15, 2024 SEC file no. 021-526663 · accession 0001683168-24-007114 |
|---|---|
| Raise progress | $14,754,032 sold of Indefinite offered · Indefinite remaining |
| Filing timing | Date of first sale: Sep 26, 2024 · Form D filed: Oct 15, 2024 (19 days after first sale) Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn. |
| Time since first sale | 758 days (2.1 years) |
| Annual amendments | Issuer reported the offering is not expected to last more than one year. Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn. |
| Investors | 43 total · issuer reported no non-accredited investors |
| Exemption claimed | Rule 506(b) — no general advertising; up to 35 non-accredited investors allowed |
| Minimum investment accepted | $0 |
| Securities offered | Equity |
| Industry / issuer size | Biotechnology · revenue range: Decline to Disclose |
| Who is paid to sell it | No sales compensation recipients listed on this filing. |
| Money to insiders | Sales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0 |
| Signed by | Daniel Haders, Chief Executive Officer (Oct 11, 2024) |
| Market context | Minimum investment: $0. Typical range for similar offerings: $10,000–$50,000. Offering size: Indefinite. Typical range: $2,000,000–$19,999,994. Investors: 43. Typical range: 2–16. "Similar" = Biotechnology offerings claiming 506(b) filed in the last 5 years (3,253 filings); ranges are the middle half (25th–75th percentile). No ranking or score. |
| Source | This filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set |
| Filing | Form D filed Feb 7, 2024 SEC file no. 021-504558 · accession 0001892786-24-000002 |
|---|---|
| Raise progress | $950,000 sold of $2,000,000 offered (48%) · $1,050,000 remaining |
| Filing timing | Date of first sale: Dec 21, 2023 · Form D filed: Feb 7, 2024 (48 days after first sale) Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn. |
| Time since first sale | 1,038 days (2.8 years) |
| Annual amendments | Issuer reported the offering is not expected to last more than one year. Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn. |
| Investors | 10 total · issuer reported no non-accredited investors |
| Exemption claimed | Rule 506(b) — no general advertising; up to 35 non-accredited investors allowed |
| Minimum investment accepted | $0 |
| Securities offered | Debt; Option, warrant or other right to acquire; Security to be acquired upon exercise; Other: Convertible Promissory Notes and Warrants |
| Industry / issuer size | Biotechnology · revenue range: Decline to Disclose |
| Who is paid to sell it | No sales compensation recipients listed on this filing. |
| Money to insiders | Sales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0 |
| Signed by | Daniel Haders, Chief Executive Officer (Feb 6, 2024) |
| Market context | Minimum investment: $0. Typical range for similar offerings: $10,000–$50,000. Offering size: $2,000,000. Typical range: $2,000,000–$19,999,994. Investors: 10. Typical range: 2–16. "Similar" = Biotechnology offerings claiming 506(b) filed in the last 5 years (3,253 filings); ranges are the middle half (25th–75th percentile). No ranking or score. |
| Source | This filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set |
| Filing | Form D filed Nov 9, 2021 SEC file no. 021-420411 · accession 0001683168-21-005331 |
|---|---|
| Raise progress | $3,500,000 sold of $3,500,000 offered (100%) · $0 remaining |
| Filing timing | Date of first sale: Aug 12, 2020 · Form D filed: Nov 9, 2021 (454 days after first sale) Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn. |
| Time since first sale | 2,264 days (6.2 years) |
| Annual amendments | Issuer reported the offering may last more than one year. Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn. |
| Investors | 5 total · issuer reported no non-accredited investors |
| Exemption claimed | Rule 506(b) — no general advertising; up to 35 non-accredited investors allowed |
| Minimum investment accepted | $0 |
| Securities offered | Security to be acquired upon exercise |
| Industry / issuer size | Other Technology · revenue range: Decline to Disclose |
| Who is paid to sell it | No sales compensation recipients listed on this filing. |
| Money to insiders | Sales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0 |
| Signed by | Daniel Haders, Chief Executive Officer (Nov 9, 2021) |
| Market context | Minimum investment: $0. Typical range for similar offerings: $5,000–$50,000. Offering size: $3,500,000. Typical range: $1,100,015–$10,001,163. Investors: 5. Typical range: 2–14. "Similar" = Other Technology offerings claiming 506(b) filed in the last 5 years (17,390 filings); ranges are the middle half (25th–75th percentile). No ranking or score. |
| Source | This filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set |
All Form D filings for this CIK on SEC EDGAR ↗. History: 2 new offerings in the last 12 months · most recent filing Oct 21, 2026 · industry as reported over time: Other Technology → Biotechnology → Other.
| Name | Relationship | Address state | On filings | Also listed on |
|---|---|---|---|---|
| Daniel Haders | Executive Officer President | CA | Nov 9, 2021 → Oct 21, 2026 | — |
| Kip Quackenbush | Executive Officer, Director | CA | Nov 9, 2021 → Oct 15, 2024 | 2 other issuers |
| Marlon Evans | Executive Officer, Director | CA | Nov 9, 2021 → Oct 15, 2024 | 3 other issuers |
Executive officers, directors and promoters as self-reported by the issuer. Licensed persons: FINRA BrokerCheck ↗ · SEC IAPD ↗.
Other issuers listing the same people:
Shared address: this business address appears on no other issuer's filings in our index.
Not yet searched. Sources to be searched: SEC Investment Adviser Public Disclosure (IAPD) firm search — registered and exempt reporting advisers · Search queued. Results are added automatically; check back later.
Not yet collected. We store official links only (company website, verified via a profile claim) and the earliest archived date of the website; never personal or family accounts.
Export this report as PDF (all source links + data timestamp; members)
No corrections have been requested for this page.
The complete public-record profile for Model Medicines, Inc., plus the weekly new-filings list.
Only "Connect me" shares your details — with this sponsor, at a flat price we charge them, never tied to whether you invest. "Just researching" shares nothing.
Free. Tell us what's wrong and, if you can, where the correct public record is. Every request is logged with its status (received → under review → fixed / confirmed with source).
Sponsors may add a sourced explanation next to any fact on this page. Reviewed before publishing; never edits the public record.
Free. Get the "Claimed by sponsor" chip and a verified contact for corrections. Claiming never changes the public-record section.